Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2018 - 2025)

X4 Pharmaceuticals' Cash from Financing Activities history spans 8 years, with the latest figure at $146.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 108116.3% year-over-year to $146.1 million; the TTM value through Dec 2025 reached $238.6 million, up 1075.85%, while the annual FY2025 figure was $238.6 million, 1075.85% up from the prior year.
  • Cash from Financing Activities reached $146.1 million in Q4 2025 per XFOR's latest filing, up from $86.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $146.1 million in Q4 2025 to a low of -$4.4 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $31.7 million, with a median of $20.2 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: crashed 1521.54% in 2021, then surged 108116.3% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $24.6 million in 2021, then surged by 146.82% to $60.6 million in 2022, then plummeted by 99.84% to $97000.0 in 2023, then skyrocketed by 39.18% to $135000.0 in 2024, then soared by 108116.3% to $146.1 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Cash from Financing Activities are $146.1 million (Q4 2025), $86.9 million (Q3 2025), and $5.6 million (Q2 2025).